PDC*line Pharma 's Intellectual Property relies on three pillars: • Proprietary PDC*line: PDC*line is unique and is the only cell line of human DCs for therapeutic use. A Master Cell Bank manufactured under GMP pro-cedures has been fully characterized and validated for biological safety. This Master Cell Bank repre-sents one of the main assets and protection for PDC*line Pharma as it is impossible to reproduce. • Patent Protection o One granted international patent family (co-in-vented by Joel PLUMAS, exclusive license from EFS) protects the therapeutic use of any Plasmacytoid DC lines (WO 2009/138489). o Four newly filed patent families protecting genetic optimizations of PDC*line (2018, filed by EFS and PDC*line Pharma; WO 2020/083974), the dosage of PDC*lung and its combination with anti-PD-(L)1 (2023, filed by PDC*line Pharma), and the method for preparing plasmacytoid dendritic cells (2023, filed by PDC*line Pharma). • Strong expertise and a large set of data accumulated over more than 20 years in the fields of pre-clinical data, manufacturing process, Quality Control and immuno-monitoring in vitro assays.